FDA Approves First-of-Its-Kind Targeted Therapy for Metastatic Pancreatic Cancer

A new targeted treatment has been approved in the United States for people with metastatic pancreatic adenocarcinoma, offering a new option for one of the most difficult cancers to treat.

The U.S. Food and Drug Administration announced on August 26 that it has approved Rasonque, also known as daraxonrasib, for certain adults with advanced pancreatic cancer. The once-daily tablet is the first approved therapy in its class and works by targeting multiple forms of RAS, a protein that helps drive tumor growth in most cases of pancreatic adenocarcinoma.

The approval applies to adults whose cancer has spread to other parts of the body and who have already received at least one systemic treatment, as well as patients who are not candidates for multiagent systemic therapy.

A major challenge in pancreatic cancer

Pancreatic cancer has long been considered especially difficult to treat. The disease is often diagnosed after it has already spread, and treatment options for advanced cases have historically been limited.

Pancreatic adenocarcinoma is by far the most common form of the disease. According to information cited by the FDA from the National Cancer Institute, it accounts for around 90% to 95% of the roughly 67,000 new pancreatic cancer cases diagnosed in the United States each year.

Although pancreatic adenocarcinoma represents only a relatively small percentage of all cancer diagnoses, it is responsible for a disproportionately high number of cancer deaths. That makes new treatment approaches particularly important.

The newly approved drug is designed to interfere more directly with a biological pathway that helps many pancreatic tumors grow. RAS proteins act like molecular switches inside cells, helping regulate growth and survival. When the pathway becomes abnormally active, it can contribute to uncontrolled cancer growth.

By inhibiting multiple forms of RAS, daraxonrasib is intended to attack a key driver of the disease rather than relying solely on traditional chemotherapy.

Trial showed longer survival

The FDA based its approval in part on results from a randomized, open-label, multicenter clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma.

In the trial, patients who received Rasonque had a median overall survival of 13.2 months. For patients receiving standard chemotherapy, median overall survival was 6.7 months.

That does not mean every patient will experience the same result, and the treatment is not described as a cure. However, the difference in median survival was substantial, giving patients and doctors another potential option in an area where new treatments are urgently needed.

The agency also moved unusually quickly. According to the FDA, the approval came around 6.5 months before the drug's user-fee deadline.

Rasonque had previously received Breakthrough Therapy and Orphan Drug designations, as well as Priority Review. These programs are designed to support or speed the development and review of treatments for serious diseases, particularly when existing options are limited.

Earlier access had already begun

Before the full approval, the FDA had also allowed the manufacturer to begin an expanded-access treatment protocol. That program made it possible for some eligible patients to receive the investigational treatment before the agency completed its review.

As with any cancer medicine, the new therapy can cause side effects. The FDA lists rash, diarrhea, inflammation of the mouth, nausea, fatigue, vomiting, abdominal pain, swelling, decreased appetite and bleeding among the most common side effects.

For patients, the decision to use the drug will therefore depend on individual circumstances and should be made together with an oncology team.

A new option where choices have been limited

The significance of the approval is not that pancreatic cancer has suddenly become easy to treat. It has not. Instead, the milestone adds a new targeted option for patients with metastatic disease at a stage where choices can be extremely limited.

It also reflects a broader shift in cancer treatment toward therapies aimed at specific molecular drivers of tumors. For pancreatic cancer, where progress has often been slower than for many other cancers, successfully targeting RAS has been a particularly important goal.

Rasonque was developed by Revolution Medicines, which received the FDA approval.

For patients and families facing advanced pancreatic cancer, the new treatment represents something that has historically been difficult to find in this disease: another meaningful option, backed by evidence of longer survival in a large clinical trial.